The close of the brief wreath-making season reminds columnist Kristin Neva how much different it is than being a long-term ...

NUZ-001, an investigational oral therapy for ALS, is officially the ninth compound to be included in the HEALEY ALS platform ...

The FDA has cleared the initiation of a pivotal Phase 3 trial testing pridopidine in people with early, rapidly progressive ...

Last year's intention "to be" made keeping a regular routine difficult for columnist Dagmar Munn, who intends now to live in ...

Qalsody is one step closer to being covered by public Canadian healthcare systems when used to treat adults with ALS with ...

ALS medication AMX0114 has been well tolerated in early clinical testing, and is now moving to a second, higher-dose trial ...

Columnist Juliet Taylor and her late husband, Jeff, fought hard for precious holiday moments after he was diagnosed with ALS.

Neurosense Therapeutics said it will seek conditional approval of PrimeC as an ALS treatment in Canada in mid-2006.

Slowing down in a fast-paced world while living with ALS isn’t surrendering, writes columnist. It’s an active choice to be ...

The ALS Association awarded a $1 million grant to support a clinical trial testing Pasithea's MEK inhibitor PAS-004 in people ...

Researchers have developed a novel approach to detect ALS and predict survival by measuring genetic activity in blood cells, a study found.

Actor Eric Dane is joining nonprofit Target ALS on a campaign aiming to raise $500,000 for ALS research by Dec. 31.